An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
NCT03266003 is an interventional trial sponsored by Centers for Disease Control and Prevention. As of 21 Nov 2026, it is completed. It studies Adherence, Medication, Adherence, Patient and 2 more conditions. The registry lists an enrollment of 216 participants at 4 sites in 1 country. The registry lists a start date of 19 Jul 2017 and a primary completion date of 10 Jan 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03266003 |
| Status | Completed |
| Study type | Interventional trial |
| Lead sponsor | Centers for Disease Control and Prevention |
| Enrollment | 216 |
| Registered sites | 4 |
| Countries | 1 |
| Conditions | Adherence, Medication, Adherence, Patient, Drug-resistant Tuberculosis and Tuberculosis |
| Start | 19 Jul 2017 |
| Primary completion | 10 Jan 2020 |
| Study completion | 31 Dec 2020 |
| Last update posted | 2 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joseph Burzynski, MD, MPH
New York City DOHMH, Bureau of Tuberculosis Control
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fort Greene Chest Center
Brooklyn
- Corona Chest Center
Jackson Heights
- Washington Heights Chest Center
New York
- Morrisania Chest Center
The Bronx
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT03266003
Each answer restates registry values shown on this page.
What is NCT03266003?
NCT03266003 is an interventional trial sponsored by Centers for Disease Control and Prevention. It studies Adherence, Medication, Adherence, Patient and 2 more conditions.
Who leads NCT03266003?
The registry names Joseph Burzynski, MD, MPH (principal investigator, New York City DOHMH, Bureau of Tuberculosis Control) as the overall official.
Where does NCT03266003 run?
The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.
When did NCT03266003 end?
The registry lists a primary completion date of 10 Jan 2020 and a study completion date of 31 Dec 2020. The sponsor last updated the record on 2 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.